1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy.
Saved in:
| Title: | 1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy. |
|---|---|
| Authors: | Starodub, A.N.1 (AUTHOR), Kim, S-B.2 (AUTHOR), Davar, D.3 (AUTHOR), Powderly, J.4 (AUTHOR), Hill, A.G.5 (AUTHOR), Yeku, O.6 (AUTHOR), Gabrail, N.7 (AUTHOR), Krapp, C.8 (AUTHOR), Pihl, S.9 (AUTHOR), Chen, M.10 (AUTHOR), Slavsky, S.11 (AUTHOR), Torrejon Castro, D.11 (AUTHOR), Singel, S.M.12 (AUTHOR), Kwatra, V.13 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS628-S628. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.2173 |
